Isolated peptides to treat alpha-synuclein diseases
US7605133B2 · kind B2 · utility
0Cited by
2References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2004 |
| Grant date | Oct 20, 2009 |
| Priority date | — |
| Expiry date | Jun 9, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by α-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.